紫杉醇是一個相當具有抗癌活性的藥劑，但由於它在水中溶解度極低，僅僅只有6 ppm (w/v)，使得在藥物輸送上產生很大的困難性。美國食品藥物管理局（FDA）已允准紫杉醇可用於乳癌、卵巢癌以及非小細胞肺癌。而目前臨床上所使用的配方，為聚氧乙烯蓖麻油Cremophor EL和無水酒精各佔體積比50%，但這配方在人體中產生了過敏現象以及利用注射液稀釋時將產生沈澱現象。所以希望藉由本實驗研究可以解決這些問題。
本實驗研究，主要在於利用混合界劑來穩定乳液配方，並且對於紫杉醇具有較高的溶解度。所以，必須先找出對於紫杉醇有較高溶解度的油相，並且這些油相具有生物相容性。再來，須找出對於油相溶解度高的混合界面活性劑系統，如此才可能包覆大量的疏水性藥物。再者，由於希望可在臨床上使用，為了滿足靜脈注射的需求，其乳液的粒徑必須落在70 nm~200 nm之間並且具有相當地穩定性。
而實驗結果顯示，在我們所選擇的油相中，包括食用油、三酸甘油酯、飽和酯類，篩選出三丁酸甘油酯、己酸乙酯、辛酸乙酯對於紫杉醇有較高的溶解度，溶解度分別為28000 ppm (w/v)、12000 ppm (w/v)、ppm (w/v)。而在找尋混合界面活性劑系統中，發現了兩個較為穩定的系統，分別為 (P 74/Tween 80) 和 (P 74/Cremophor EL) 系統。這兩個系統對於三丁酸甘油酯以及己酸乙酯分別在0.3 ～0.5 ％ 以及 0.5～0.8％可形成穩定微乳液。如此乳液對於紫杉醇理論包覆可達120～150ppm，這將使得此系統有潛力成為紫杉醇之藥物載體，並且值得更進一步的研究。

Paclitaxel is a promising anti-cancer agent but with poor water solubility (6 ppm (w/v)). The U.S. Food and Drug Administration has approved Taxol for use against breast cancer、ovarian cancer and non-small cell lung cancer. The current clinical formulation is 50:50 (v/v) mixture of cremophor EL and dehydrated ethanol which causes hypersensitivity reaction and precipitates upon dilution .So, we hope to solve the problems by the research.
The study focus on that mixed surfactant stabilized emulsion and larger amount of paclitaxel can be incorporated. First, it must find out suitable oils which can dissolve larger amount of drugs and posses biocompatibility. Furthermore, searching that the mixed surfactants can dissolve higher amount of screened oils. Thus, larger amounts of drugs can be encapsulated by the o/w emulsion. Moreover, the particle size of the emulsion ranges from 70nm to 200nm which meet the requirement for intravenous administration.
The research results reveal that tributyrin, ethyl caproate, ethyl caprylate have higher solubility for paclitaxel among the chosen oils including edible oils, triglycerides, fatty ester. The paclitaxel solubility in tributyrin, ethyl caproate and ethyl caprylate are around 28000 ppm (w/v), 12500 ppm (w/v) and 5000 ppm (w/v). We found out two more stable system in searching for mixed surfactant system. They are the combination of P 74/Tween 80 and P 74/ Cremopher EL. The two systems forms stable microemulsion by changing P 74/Tw 80 ratio from 0.66 to 1.5. The formulations contain 0.3%~0.5% tributyrin or 0.5%~0.8% ethyl caproate in the emulsion.Hence, up to 120~150 ppm of paclitaxel can be encapsulated and paclitaxel solubility was greatly enhanced.the paclitaxel delivery systems are promising and are worth further investigation.

Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R：“Taxol: a history of pharmaceutical development andcurrent pharmaceutical concerns.” J Natl Cancer Inst 15: 141–147, (1993)

Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM: “A mixed micellar formulation suitable for the parenteral administrationof Taxol.” Pharm Res 11: 206–212, (1994)

Amarnath Sharma, Robert M. Straubinger, “Novel Taxol Formulations : Preparation and Characterization of Taxol-Containing Liposomes ”.Pharmaceutical Research, Vol. 11,No. 6, pp 889-896, (1994)

Amarnath Sharma, Uma S. Sharma, “Review : Liposomes In Drug Delivery: Progress and Limitations ”. International Journal of Pharmaceutics 154, pp123-140, (1997)

Andersson, Borje S., “Parenteral Paclitaxel in a Stable Non-Toxic Formulation”, United State Patent 5877205,March 2, (1999)

Bartoli MH, Boitard M, Fessi H, Beriel H, Devissaguet JP, Picot F, Puisieux F: “In vitro and in vivo antitumoral activityof free, and encapsulated taxol.” J Microencapsulation 7: 191–197, (1990)

Bartoli H., Boitard M., Fessi H.,Beriel H., Devissagnet J.P., Picot F., Puisien,F., “In Vitro And IN Vivo Antitumoral Activity of Free And Encapsulated Taxol.” Journal of Microencapsulation 7, pp191-197, (1990)

Becher, P., “in Pesticide formulations”, W. Van Valkenburg (Ed.), New York, Marcel Dekker, P. 85;1973b,p. 84, (1973)

Becher, P., “Emulsions. Theory and Practice,3rd ed”., American Chemical Society, Washington, DC, (2001)

Bourell M And Schechter RS, “Microemulsions and Related Systems”. Marcel Dekker, New York, (1998)

Burt HM, Jackson JK, Bains SK, Liggins RT, Oktaba AM,Arsenault AL, Hunter WL. “Controlled delivery of taxol frommicrospheres composed of a blend of ethylene-vinyl acetatecopolymer and poly (d,l-lactic acid).” Cancer Lett 88: 73–79, (1995)

Christian Von Corswant, Peter Thoren And Sven Engstom, “Triglyceride Based Microemulsion For Intravenous Administration of Sparingly Soluble Substances”. Journal of Pharmaceutical Sciences, Vol.87,No.2, (1998)

Dordunoo SK, Jackson JK, Arsenault LA: “Taxol encapsulationin poly(_-caprolactone) microspheres.” Cancer ChemotherPharmacol 36: 279–282, (1995)

Hayat Alkan-Onyuksel, Suganthi Ramakrishnan, Hee-Byung Chai, John M. Pezzuto, “A Mixed Micellar Formulation Suitable For The Parental Administration of Taxol.”
Pharmaceutical Research, Vol. 11, No.2, pp206-212, (1994)

Jonkman-de Vries JD, Flora KP, Bult A, Beijnen JH: “Pharmaceuticaldevelopment of (investigational) anticancer agentsfor parenteral use – a review.” Drug Develop Indust Pharm 22:475–494, (1996)

Kan P, Chen ZB, Lee CJ, Chu IM, “Study on The Formulation of O/W Emulsion As Carriers For Lyophilic Drugs”. Colloids and Surfaces B:Biointerfaces 15, pp117-125, (1999)

Kan P, Chen ZB, Lee CJ, Chu IM, “Development of Nonionic Surfactant / Phospholipid O / W Emulsion As A Paclitaxel Delivery System”. Journal of Controlled Release 58, pp 271-278, (1999)

Liu F And Liu D, “Amphipathic Polyethylene Glycol Stabilized Emulsions(O/W):Physical Characterization And In Vivo Distribution”. International Journal of Pharmaceutics 125, pp 73-80, (1995a)

Liu F. And Liu D., “Long-Circulating Emulsions (Oil-In-Water) As Carriers For Lipophlic Drugs”. Pharmaceutical Research, Vol. 12, No.7, pp1060-1064, (1995b)

Lundberg Bo, “Preparation of Drug-Carrier Emulsions Stabilized With Phosphatidylcholine -Surfactant Mixtures”. Journal of Pharmaceutical Sciences, Vol.83,No.1,pp72-75, (1994a)

Lundberg Bo, “The Solubilization of Lyophilic Derivatives of Podophylotoxins in Sub-Micron Sized Lipid Emulsions and Their Cytotoxic Activity Agaist Cancer Cells in Culture”. International Journal of Pharmaceutics 109, pp73-81, (1994b)

Lundberg BB, Mortimer BC,Redgrave TG, “Submicron Lipid Emulsions Containing Amphipathic Polyethylene Glycol for use as Drug-Carriers With Prolonged Circulation Time”. International Journal of Pharmaceutics 134, pp119-127, (1996)

Lundberg BB: “A submicron lipid emulsion coated with amphipathicpolyethylene glycol for parenteral administration ofpaclitaxel (Taxol).” J Pharm Pharmacol 49: 16–21, (1997)

Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ: “Synthesis and evaluation of some water-soluble prodrugs andderivatives of Taxol with antitumor activity.” J Med Chem 35:145–151, (1992)

Mellado W, Magri NF, Kingston DGI, Garcia-Arenas R, Orr GA, Horwitz SB: “ Preparation and biological activity of taxolacetates.” Biochem Biophys Res Com 124: 329–336, (1984)

Myers Drew “Surfaces, Interfaces, And Colloids: Principle And Applications”, Wiley-Vch , (1999)
Paradis R, Pag M: “New active paclitaxel amino acids derivativeswith improved water solubility.” Anticancer Res 18:2711–2716, (1998)

Park KM, Lee MK, Hwang KJ, Kim CK, “Phospholipid-Based Microemulsions of Flurbiprofen By The Spontaneous Emulsification Process”. International Journal of Pharmaceutics 183, pp145-154, (1999)

Product information Taxotere ( Rhne-Poulenc Rorer)

Product information Taxol (Bristol-Myers Squibb, Princeton,US)

Ramesh Panchagnula, “Review： Pharmaceutical Aspects of Paclitaxel”. International Journal of Pharmaceutics 172, pp 11-15, (1998)

Rowinsky E., Donehower R.C., “Paclitaxel ( TAXOL)”. NEW England J. Med. 332, pp 1004-1014, (1995)

Sharma D, Chelvi TP, Chakravorty K, De TK, Maitra A, Ralhan R: “Novel Taxol formulation: polyvinylpyrrolidonenanoparticle-encapsulated Taxol for drug delivery in cancertherapy.” Oncol Res 8: 281–286, (1996)

Simamora P, Dannenfelser RM, Tabibi SE, Yalkowski SH : “Emulsion formulations for intavenous administration of paclitaxel.” PDA J Pharm Sci Technol 52: 170–172, (1998)

Sweetana S, Akers MJ: “Solubility principles and practices forparenteral drug dosage form development.” PDA J Pharm SciTechnol 50: 330–342, (1996)

Tarr BD, Sambandan TG, Yalkowsky SH, “A New Parenteral Emulsion For The Administration of Taxol”. Pharmaceutical Research, Vol.4,No.2, pp162-165, (1987)

Ueda Y, Mikkilineni AB, Knipe JO, Rose WC, Casazza AM, Vyas DM: “Novel water soluble phosphate prodrugs of Taxolrpossessing in vivo antitumor activity.” Bioorganic Med ChemLett 3: 1761–1766, (1993)

Ueda Y, Wong H, Matiskella JD, Mikkelineni AB, FarinaV, Fairchild C, Rose WC, Mamber SW, Long BH, Kerns EH, Casazza AM, Vyas DM: “Synthesis and antitumor evaluationof 20-oxycarbonylpaclitaxels (paclitaxel-20 -carbonates).”Bioorganic Med Chem Lett 4: 1861–1864, (1994)

Vyas DM, Wong H, Crosswell AR, Casazza AM, Knipe JO, Mamber SW, Doyle TW: “Synthesis and antitumor evaluationof water soluble taxol phosphates.” Bioorganic Med Chem Lett3: 1357–1360, (1993)

Vyas DM: “Paclitaxel (Taxol○R) formulation and prodrugs.” In: Farina V (ed) The Chemistry and Pharmacology of Taxol andits Derivatives, 103–130, (1995)

Washington C., “Stability of Lipid Emulsion For Drug Delivery“. Advanced Drug Delivery Reviews20, pp131-145, (1996)

Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, Oktaba AM, Hunter WL: “An investigation of theantitumour activity and biodistribution of polymeric micellarpaclitaxel.” Cancer Chemother Pharmacol 40: 81–86, (1997)

Zhang X, Burt HM, Mangold G, Dexter D, Von Hoff D, Mayer L, Hunter WL: “Anti-tumor efficacy and biodistribution of intravenouspolymeric micellar paclitaxel.” Anticancer Drugs 8:696–701, 1997

趙承琛,“界面科學基礎第三版”,復文書局, 2006